Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Investigation of Proton Treatment in Hodgkin Lymphoma Patients - PRO-Hodgkin
Sponsor: Uppsala University Hospital
Summary
Hodgkin Lymphoma patients with limited stage are commonly cured with limited chemotherapy followed by radiotherapy. Studies have shown a risk of late toxicity from the radiotherapy, such as second cancer, heart failure and lung toxicity. With proton therapy the dose to normal tissue can be minimised without compromising the dose to the tumor. The aim of our study is to investigate whether proton therapy can be delivered in a safe way to Hodgkin Lymphoma patients with less late side effects than conventional radiotherapy, while retaining the high cure rate. This is a multicentre phase II study of PBS proton beam therapy in patients ≤60 years, with early stage Hodgkin Lymphoma treated with induction chemotherapy. The study is performed in a non-inferiority setting comparing with a historical population-based consecutive Swedish material. The control group was treated according to the same principles, except that the radiotherapy was delivered with photons.
Official title: Clinical Investigation of PBS Proton Treatment in Hodgkin Lymphoma Patients - PRO-Hodgkin
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
75
Start Date
2019-09-01
Completion Date
2041-06
Last Updated
2025-03-19
Healthy Volunteers
No
Conditions
Interventions
Proton therapy.
Pencil beam scanning proton therapy to a dose of 20 or 29.75 Gy (RBE) after standard chemotherapy (2-4 ABVD).
Locations (6)
Sahlgrenska University Hospital
Gothenburg, Sweden
Skane University Hospital
Lund, Sweden
Orebro University Hospital
Örebro, Sweden
Karolinska University Hospital
Solna, Sweden
Umea University Hospital
Umeå, Sweden
Uppsala University Hospital
Uppsala, Sweden